Search Results 441-450 of 16868 for Antagonist

1. A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer - Mayo Clinic

   ... antagonist) prior to the first dose of study drug and must continue this therapy throughout the treatment phase * Palliative radiotherapy (for example \[eg ...

2. Abiraterone/Prednisone, Olaparib, Or Abiraterone/Prednisone + Olaparib In Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects - Mayo Clinic

   Patients must continue primary ADT with an LHRH analogue (agonist or antagonist) if they have not undergone orchiectomy. Able to take oral medication ...

3. Clinical trials - Oncology (Medical)

   Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With ...

4. Publications - Ephraim E. Parent, M.D., Ph.D. - Mayo Clinic

   Synthesis and biological evaluation of a fluorine-18-labeled nonsteroidal androgen receptor antagonist, N-(3-[18F]fluoro-4-nitronaphthyl)-cis-5-norbornene ...

5. Prescription of Letrozole for Uterine Myoma - Mayo Clinic

   * Leiomyomata treated by GRNH agonist or antagonist in the last 12 weeks; or plans to use the above in the next 24 weeks * Currently pregnant or lactating ...

6. Ondansetron (oral route, oromucosal route) - Mayo Clinic

   Make sure you tell your doctor if you have any other medical problems, especially: Allergy to other selective 5-HT3 receptor antagonists (eg, alosetron [ ...

7. Olmsted County, Minnesota Air Quality (OMAQ) Study - Mayo Clinic

   Asthma (history of physician diagnosis of asthma + on asthma controller medication [eg, inhaled corticosteroid, leukotriene receptor antagonist]. Currently ...

8. A Study to Evaluate the Safety and Effectiveness of Ustekinumab Induction and Maintenance Therapy in Participants with Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

   OR has not had biologic therapy (TNF antagonists or vedolizumab); Has received biologic therapy but has not demonstrated a history of failure to respond to ...

9. Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma - Mayo Clinic

   Prior therapy with a Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) or Programmed death- 1 (PD-1) antagonist, or Programmed cell death- ligand 1 (PD-L1) or CD137 ...

10. Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function - Mayo Clinic

    Aldosterone antagonist, antiarrhythmic medications and other vasodilators will be allowed; however, all medications must be at stable doses 4 weeks prior to ...